Follow

Today is the first day of trading in DanCann Pharma A/S shares and warrants at Spotlight Stock Market

12 November 2020 - 08:30

Today is the first day of trading in DanCann Pharma A/S ("DanCann Pharma") shares and warrants of series TO 1. DanCann Pharma’s shares are traded under the ticker "DANCAN" with ISIN DK0061410487 and DanCann Pharma’s warrants of series TO 1 are traded under the ticker "DANCAN TO 1" with ISIN DK0061410560.

DanCann Pharma was provided approximately DKK 30 million (before issue costs) in the oversubscribed IPO of units which resulted in more than 1 600 new shareholders. The total number of shares in DanCann Pharma is 20 730 800 shares and the share capital amount to DKK 777 405. In addition, there are a total of 2 668 000 warrants of series TO 1 issued. Each warrant of series TO 1 entitles the holder the right to subscribe for one (1) new share in DanCann Pharma at a subscription price of DKK 6 per share during the exercise period September 1, 2021 until September 17, 2021.

Financial advisor, legal advisor and issuing agent

Corpura Fondkommission AB is the financial advisor of DanCann Pharma in connection with the issue of units. Andersen Partners Advokatpartnerselskab is acting as legal advisor. Nordic Issuing is acting as issuing agent. For additional information regarding the IPO, please contact:

Corpura Fondkommission AB
E-mail: info@corpura.se

About DanCann Pharma

DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
Email:
jkr@dancann.com
Website: www.dancann.com

Provided by: Cision
Spotlight (Sweden)
Dancann Pharma A/S
DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma makes and distributes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date